Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
•
5 likes•3,213 views
- Recorded videos of this lecture: English Language version of this lecture is available at: https://youtu.be/kanEHVsStsI - Visit our website for more lectures: www.NephroTube.com - Subscribe to our YouTube channel: www.youtube.com/NephroTube - Join our facebook group: www.facebook.com/groups/NephroTube - Like our facebook page: www.facebook.com/NephroTube - Follow us on twitter: www.twitter.com/NephroTube
Recommended
More Related Content
What's hot
What's hot (20)
Similar to Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
Similar to Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad (20)
More from NephroTube - Dr.Gawad
More from NephroTube - Dr.Gawad (20)
Recently uploaded
Recently uploaded (20)
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
- 1. Insights from the FIGARO-DKD and FIDELIO-DKD trials Mohammed Abdel Gawad MD, ESENeph Lecturer of Nephrology, School of Medicine, NewGiza University, Giza Nephrology Consultant, Abu Kier Insurance Hospital, Alexandria Founder of NephroTube.com
- 2. To download the lecture contact me drgawad@gmail.com For more Nephrology lectures visit www.NephroTube.com
- 4. Journal of The Egyptian Society of Nephrology and Transplantation 2022, 22:1–28
- 5. Kidney News. 2022. 14(1)
- 6. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 7. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 8. Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes Kidney Int Suppl. 2013; 3: 1–150
- 9. Kidney Int Suppl. 2013; 3: 1–150
- 10. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 11. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 12. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004
- 13. Eur Heart J. 2021 Jan 7;42(2):152-161
- 14. Nephrol Dial Transplant. 2022 May 25;37(6):1014-1023
- 15. Nephrol Dial Transplant. 2022 May 25;37(6):1014-1023
- 16. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 17. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 19. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 20. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 21. Kidney News. 2022. 14(1)
- 22. Kidney News. 2022. 14(1)
- 23. Overlap of patient populations according to inclusion values for UACR and eGFR in the FIDELIO-DKD and the FIGARO-DKD trials Nephrol Dial Transplant. 2022 May 25;37(6):1014-1023
- 24. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 25. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 26. FIDELIO-DKD and FIGARO-DKD endpoints Nephrol Dial Transplant. 2022 May 25;37(6):1014-1023
- 27. Kidney News. 2022. 14(1)
- 28. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis Eur Heart J. 2022 Feb 10;43(6):474-484
- 29. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis Eur Heart J. 2022 Feb 10;43(6):474-484
- 30. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 31. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 32. Kidney News. 2022. 14(1)
- 33. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis Eur Heart J. 2022 Feb 10;43(6):474-484
- 34. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 35. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 36. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis Eur Heart J. 2022 Feb 10;43(6):474-484
- 37. Nephrol Dial Transplant. 2021 Nov 25;gfab336. Patients from FIDELIO-DKD who met the CKD inclusion criteria of the CREDENCE study were included in this analysis.
- 38. Nephrol Dial Transplant. 2021 Nov 25;gfab336.
- 39. Nephrol Dial Transplant. 2021 Nov 25;gfab336.
- 40. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 41. Talk Outline • Albuminuria and eGFR for CV risk assessment • Aldosterone pathophysiological effects • FIDELIO-DKD, FIGARO-DKD trials and FIDELITY: oPatient populations oEndpoints oSafety • Finerenone – SGLT2 inhibitors relationship • Summary and Thoughts
- 42. • The assessment of CV and kidney failure risk must include both eGFR and UACR. • Abnormal UACR in patients with eGFR ≥60 is considered as CKD. • Finerenone is effectively reduces CV and kidney failure outcomes in patients with CKD + T2D. • Should finerenone be used in combination with SGLT2 inhibitors? • Should finerenone be used with novel oral potassium binders, etc.? Summary and Thoughts